Our Science

Scientific Conference Presentations – 2016

Presentations presented at 2016 Superbugs & Superdrugs USA, Iselin, NJ, November 2016:

Presentation Title: Addressing the evolving challenge of β-lactamase mediated antimicrobial resistance:  ETX2514, a next-generation BLI with potent broad-spectrum activity against Class A, C and D enzymes
Presented by: Alita Miller
Meeting: 2016 Superbugs & Superdrugs USA, 2016

Presentations presented at ID Week, New Orleans, October 2016:

Presentation Title: Microbiological Cure Rates and Antimicrobial Susceptibility of Neisseria gonorrhoeaeto ETX0914 (AZD0914) in a Phase II Treatment Trial for Urogenital Gonorrhea
Presented by: Stephanie N. Taylor, MD; LSU-Crescent Care Sexual Health Center
Meeting: ID Week, 2016

Presentation Title:  Global Surveillance of the Activity of Sulbactam combined with the Novel β-lactamase InhibitorETX2514 against Clinical Isolates of Acinetobacter baumannii from 2014
Presented by:  Kenneth Lawrence
Meeting:  ID Week, 2016

Presentation Title:  Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii
Presented by:  John O’Donnell
Meeting:  ID Week, 2016

Presentation Title: Sulbactam Combined with the Novel b-lactamase Inhibitor ETX2514 for the Treatment of Multidrug-ResistantAcinetobacter baumannii Infections
Presented by:  Alita Miller
Meeting:  ID Week, 2016

Presentations presented at the CDC STD Prevention Conference, Atlanta, September 2016:

Presentation Title: A Phase II Trial of Single-Dose Oral ETX0914 (AZD0914) for Treatment of Uncomplicated Urogenital Gonorrhea
Presented by: Stephanie N. Taylor, MD; LSU-Crescent Care Sexual Health Center
Meeting: CDC STD Prevention Conference, 2016

Posters and presentations presented at ASM Microbe, Boston, June 2016:

Poster Title: A Phase II Trial of Single-Dose Oral ETX0914 (AZD0914) for Treatment of Uncomplicated Urogenital Gonorrhea
Presented by: Adam Shapiro
Meeting: ASM Microbe, 2016

Presentation Title: Addressing the Evolving Challenge of Beta-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes
Presented by: Ruben Tommasi
Meeting: ASM Microbe, 2016

Poster Title: In Vitro and In Vivo Efficacy of the Novel Beta-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii
Presented by: John O’Donnell
Meeting: ASM Microbe, 2016

Presentations presented at the American Chemical Society meeting, San Diego, March 2016:

Presentation Title: Improving our Understanding of Porin Permeability in Gram-negative Bacteria
Presented by: Thomas Durand-Reville
Meeting: ACS, 2016

Presentations presented at the Gordon Research Conference on New Approaches to Antibacterial Research & Development, Italy, March 2016:

Presentation Title: Small Molecule Inhibitors of Gram-negative Lipoprotein Trafficking
Presented by: Sarah McLeod
Meeting: GRC, 2016

Presentations presented at the Applied Pharmaceutical Chemistry meeting, Boston, April 2016:

Presentation Title: Improving our Understanding of Porin Permeability in Gram-negative Bacteria
Presented by: Thomas Durand-Reville
Meeting: APC, 2016

Presentations presented at the Boston Area Antimicrobial Research Network, Cambridge, June 2016:

Presentation Title: Challenges and Opportunities in Drug Discovery
Presented by: Alita Miller
Meeting: BAARN, 2016

 

“Our scientific approach and expertise, coupled with Entasis’ strong pipeline of programs, really make us stand out in the field of antibacterial drug discovery and development.”

— Satenig Guler, Senior Scientist